Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2012-01-30 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
详式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report". It is issued by an information disclosure obligor regarding changes in equity ownership and control of a listed company (中源协和干细胞生物工程股份公司). The content includes detailed information about the equity change, shareholding structure before and after the change, funding sources, and future plans related to the equity change. It references relevant laws and regulations about equity changes and disclosures. This type of document corresponds to a Major Shareholding Notification, which reports significant changes in share ownership levels and control. The document is lengthy (15,000 characters) and contains substantive details about the equity change, not just an announcement or a brief note. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2012-01-30 Chinese
关于召开公司2012年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening a 2012 first extraordinary general meeting (临时股东大会) of shareholders for a company, including meeting time, location, voting procedures (both onsite and online), agenda items for shareholder approval, and proxy voting instructions. It contains no financial statements or financial performance data. It is an announcement of a shareholder meeting and related voting procedures, not a report of financial results or management discussion. The content focuses on meeting logistics and resolutions to be voted on, including stock issuance and acquisition proposals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is over 5,000 characters and contains detailed agenda and voting instructions, consistent with PSI filings rather than a simple meeting notice (AGM-R) or voting results (DVA). Therefore, the classification is PSI with high confidence.
2012-01-30 Chinese
第七届董事会第七次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions from the company's seventh board meeting, including discussions and approvals related to the termination of a 2011 non-public stock issuance plan, acquisition of a 51% stake in a company called Heze Bio, and related financing and capital raising activities. It includes voting results, references to shareholder meetings, and detailed plans for non-public stock issuance, including pricing, quantity, and use of proceeds. The document also contains a feasibility report on the use of funds raised from the non-public stock issuance, and an asset valuation report related to the acquisition. The content is focused on capital raising, financing activities, and related corporate governance decisions. It is not a full annual or interim report, nor an earnings release or audit report. It is not a simple announcement of a report publication but contains substantive details on financing and capital structure changes. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2012-01-30 Chinese
非公开发行股票预案
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票预案" which translates to "Non-public Stock Issuance Proposal". It contains detailed information about a non-public offering of shares, including the background, purpose, pricing, number of shares, issuance method, use of proceeds, and related party transactions. It also includes financial data of the issuer and the subscriber, contract summaries, and board approvals. The document is lengthy (15,000 characters) and contains substantive details about the capital raising plan and its impact on the company. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an announcement of a report, nor a full annual or interim report, nor a proxy or voting announcement. Therefore, the correct classification is CAP.
2012-01-30 Chinese
关于收购和泽生物科技有限公司51%股权的关联交易公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 51% equity in a company (Heze Bio-Technology Co., Ltd.) by Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. It includes information about the transaction parties, shareholding structure, financial data, asset evaluation, pricing policy, payment terms, and independent directors' opinions. The document is titled as an "announcement" and contains detailed transaction information, including board resolutions and shareholder meeting approvals. This fits the category of a Capital/Financing Update (CAP) because it reports on a significant equity acquisition transaction and related financing details. It is not a full annual or interim report, nor a regulatory filing or proxy statement. The length and content confirm it is a substantive announcement of a financing/capital transaction.
2012-01-30 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding and control of the company 中源协和干细胞生物工程股份公司 (ST中源) by the information disclosure obligor 韩月娥. The content includes detailed information about shareholding percentages before and after the change, the nature of the equity change, and related agreements. It also references relevant Chinese securities laws and regulations governing equity changes and disclosures. The document is a formal report of a change in major shareholding and control, not an announcement of a report or a general regulatory filing. It is not an annual or interim financial report, nor a management or earnings report. It specifically concerns a change in significant share ownership and control, fitting the category of Major Shareholding Notification (MRQ). The document length (5333 characters) and detailed content support this classification with high confidence.
2012-01-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.